Eisai and PharmStandard Sign Co-Operation Agreements in Russia

Home » Eisai and PharmStandard Sign Co-Operation Agreements in Russia

Eisai and PharmStandard Sign Co-Operation Agreements in Russia

red-square-russia moscowJapanese research and development pharmaceutical company, Eisai, and PharmStandard, a leading Russian pharmaceutical company, have signed Co-operation
Agreements relating to the localized production of Eisai products in Russia.

These agreements relate to Eisai’s global oncology therapies, Halaven (eribulin) and Lenvima (lenvatinib), as well as the company’s global epilepsy therapy, Fycompa

Under the proposed agreements, important stages in the manufacturing process for both eribulin and lenvatinib will be completed in PharmStandard’s cutting edge facilities in Ufa, while for perampanel these will be performed in PharmStandard’s facility in Kursk.

Eribulin was registered in Russia in July 2012 and became accessible for patients with locally advanced or metastatic breast cancer who have progressed after at least one course of chemotherapy for advanced disease from September 2013. Lenvatinib was registered in Russia in December 2015 and will be accessible for treatment of radioactive iodine refractory differentiated thyroid cancer from June 2016.

Perampanel was registered in August 2013 in Russia as adjunctive treatment for patients with partial onset seizures, with or without secondarily generalized seizures, in patients with epilepsy aged 12 years and older.

“This is an important step forward for the establishment of Eisai in Russia. Through this arrangement with PharmStandard, we can ensure that Russian patients will have access to our innovative drugs, eribulin, lenvatinib and perampanel. Our presence in Russia continues to grow and we are pleased to partner with this leading company to increase our value to patients and their families,” commented Olga Konopleva, General Manager, Eisai Russia.

“We are pleased to partner with Eisai, one of the worldwide leaders in oncology and epilepsy, to expand the reach of their therapies and address patient needs in Russia,” comments Grigory Potapov, CEO, Pharmstandart PJSC.

This collaboration underscores Eisai’s human health care (hhc) mission, the company’s commitment to innovative solutions in disease prevention, cure and care for the health and well-being of people worldwide. Eisai is committed to epilepsy and oncology to address the unmet medical needs of patients and their families.